The CSP technology platform consists of soluble recombinant dimeric and trimeric proteins with a quaternary structure mimicking the natural conformation of protein complexes on cell surfaces, such as receptors or cancer target proteins. These recombinant dimers and trimers enable more biologically relevant translational research and therapeutic antibody discovery.
Recombinant ectodomains are genetically engineered with a proprietary cis-dimer motif and stabilization domain at the C-terminus. This promotes spontaneous dimer formation while preserving native structure and orientation. All proteins are expressed in mammalian systems to retain essential post-translational modifications.
Design features:
Class of proteins: immune chckpoint proteins, tumor associated antigens, cytokine receptor proteins, T-cell receptor proteins, growth factor receptor proteins, B-cell receptor proteins and siglec proteins
Dimerization is not just structural — it’s essential for function. Many immune receptors, such as CD4 or IFNαR1/2, rely on multimeric configurations for ligand engagement and downstream signaling. Traditional recombinant formats often fail to replicate these quaternary structures, leading to poor assay sensitivity and inconsistent biological readouts.
CSP™ dimers resolve these issues by:
CD4 Protein Dimer Binding to Ligand HIV-1 gp120
See the CD4 protein product details
Cytokine IFNα Binding to IFNα Receptor Molecules
As an Immunogen
Presents more conformational epitopes compared to monomers, to generate antibodies for translational research and therapeutic discovery
As an Antigen
Screen and characterize antibodies targeting diverse epitopes including quaternary conformational epitopes
Drug Screening
Agonist or antagonist screening for research and therapeutic discovery
Characterization
Antibody and drug bioactivity
The stability of the purified recombinant multimeric proteins is comparable to the stability of other recombinant proteins. These proteins are stable for at least 6 months when frozen (-70°C) or at least 7 days at 4°C. Like most recombinant proteins, excessive vortexing, dilution, and freeze-thaw should be avoided to minimize sample and activity loss. More information can be found on the datasheet.
The recombinant multimeric proteins can readily be modified. Please contact Conigen to request tag-free, a special tag, biotinylated or fluorescently labeled molecules.
The Conigen validation process involves various analytical techniques for each batch, including techniques such as SDS-PAGE, Western blot, and ELISA
Please contact Conigen using the Consultation request form.
Please contact Conigen using the Consultation request form.
The turnaround time of custom orders is approximately 6-8 weeks from sequence to product. Please contact Conigen using the Consultation request form for more information.
Abstract Therapeutic antibodies targeting protein conformational epitopes is crucial. The discovery of specific and functional antibodies against complex membrane proteins remains a major challenge in
Poster Abstract Antibody staining of G protein-coupled receptors (GPCRs) on live cells is important for studying receptor expression, localization, and dynamics in their native, functional
Poster Abstract CXCR4 and CXCR5 are G-protein coupled receptors (GPCRs). CXCR4 is a receptor for chemokine CXCL12 and a co-receptor for HIV to infect CD4
Conigen Bioscience is Exhibiting at Discovery on Target Poster Presentations Recombinant Bioactive CXCR4 or CXCR5 on Virus-Like Nanoparticles Can Bind to Their Chemokine Ligand CXCL12
Overview Understanding cytokine-receptor interactions is critical for advancing immunology research and therapeutic development, but capturing these interactions in a native-like state can be challenging. In
DivcoWest and BVS’ Biotech Summer BBQ Event at Cambridge Crossing Date: Wednesday, July 30, 2025Event Time: 11:00 AM – 1:30 PMLocation: 222 Jacobs St, Cambridge,
